α-Synuclein accumulation is a pathological hallmark of Parkinson's disease (PD). Ubiquitinated α-synuclein is targeted to proteasomal or lysosomal degradation. Here we identify SUMOylation as a major mechanism that counteracts ubiquitination by different E3 ubiquitin-ligases and regulates α-synuclein degradation. We report that PIAS2 promotes SUMOylation of α-synuclein, leading to a decrease in α-synuclein ubiquitination by SIAH and Nedd4 ubiquitin ligases, and causing its accumulation and aggregation into inclusions. This was associated with an increase in α-synuclein release from the cells. A SUMO E1 inhibitor, ginkgolic acid, decreases α-synuclein levels by relieving the inhibition exerted on α-synuclein proteasomal degradation. α-Synuclein disease mutants are more SUMOylated compared to the wild type protein, and this is associated with increased aggregation and inclusion formation. We detected a marked increase in PIAS2 expression along with SUMOylated α-synuclein in PD brains, providing a causal mechanism underlying the upregulation of α-synuclein SUMOylation in the disease. We also found a significant proportion of Lewy bodies in nigral neurons containing SUMO1 and PIAS2. Our observations suggest that SUMOylation of α-synuclein by PIAS2 promotes α-synuclein aggregation by two mutually reinforcing mechanisms. First, it has a direct pro-aggregatory effect on α-synuclein. Second, SUMOylation facilitates α-synuclein aggregation by blocking its ubiquitin-dependent degradation pathways and promoting its accumulation. Therefore, inhibitors of α-synuclein SUMOylation provide a strategy to reduce α-synuclein levels and possibly aggregation in PD.
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Parkinson's disease | a-synuclein | SUMOylation | ubiquitination | aggregation
Parkinson's disease (PD) is caused by progressive degeneration of dopaminergic neurons in the substantia nigra (1) . Mutations and multiplications of the α-synuclein gene cause autosomal dominant PD (2) . α-Synuclein is a major component of Lewy bodies in sporadic PD and its accumulation is also a feature of Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA) (3, 4) . It has been suggested that aggregated α-synuclein can spread to different brain regions (5) . On the other hand, primary accumulation and aggregation of intracellular α-synuclein is widely regarded as a failure of degradation mechanisms (6, 7) . Therefore, preventing α-synuclein accumulation is a major goal for novel therapies. Although α-synuclein is degraded by proteasomal, lysosomal and autophagic pathways (8) (9) (10) , the mechanisms that modulate its degradation remain obscure.
Lewy bodies are heavily ubiquitinated and α-synuclein purified from Lewy bodies is monoubiquitinated (11) (12) (13) . Several ubiquitin-ligases are capable of ubiquitinating α-synuclein (8, (14) (15) (16) (17) . The E3 ubiquitin-ligase SIAH interacts with and monoubiquitinates α-synuclein (8, 17) . SIAH is present in Lewy bodies (8) and monoubiquitinates α-synuclein at the same lysine residues that are monoubiquitinated in Lewy bodies (11, 17) . Monoubiquitinated α-synuclein is degraded by the proteasome (18) (19) (20) while polyubiquitination by Nedd4 leads to its lysosomal degradation (15) .
We previously found that the deubiquitinase USP9X dynamically deubiquitinates α-synuclein (18) . Deubiquitination of α-synuclein by USP9X impairs SIAH-dependent α-synuclein proteasomal degradation and promotes degradation by autophagy (18) . Another deubiquitinase, USP8, removes K63-linked ubiquitin chains of α-synuclein and prevents its lysosomal degradation (21) . The regulation of α-synuclein ubiquitination processes and their role in α-synuclein homeostasis are still unclear.
α-Synuclein is also conjugated to SUMO (small ubiquitinlike modifier) at lysines but its role in aggregation remains controversial (22) (23) (24) (25) . Some studies demonstrated increased α-synuclein aggregation by SUMOylation upon proteasomal inhibition (23, 24) , but SUMOylation itself had limited or no effect on aggregation (22, 25) . A lack of knowledge about the endogenous α-synuclein SUMO-ligase hampered further progress in determining the physiological and pathological functions of α-synuclein SUMOylation. Therefore, we sought to identify the endogenous SUMO ligase for α-synuclein and to determine how SUMOylation affects α-synuclein ubiquitination, degradation, and aggregation. Our data highlights a new role of SUMOylation in dynamically regulating α-synuclein levels and pathology.
Results

Interaction and SUMOylation of α-synuclein by PIAS2
We found that PIAS2 co-immunoprecipitated with α-synuclein from transfected cells (Fig. 1A) , rat brain tissues (Fig.  1B) , and in in vitro pull-down assays (Fig. S1A) . The close homologue PIAS1 also interacted with α-synuclein in transfected
Significance
Our work uncovers SUMOylation as a major regulator of α-synuclein fate and pathological aggregation. SUMOylation promotes α-synuclein accumulation by counteracting α-synuclein ubiquitination and inhibiting its degradation. SUMOylation also directly causes aggregation of α-synuclein in vitro and in cells, and the effects are much more prominent with the α-synuclein disease mutants. Most importantly, levels of SUMOylated α-synuclein and components of the SUMOylation machinery increase several fold in PD brains and are present in Lewy bodies. Our data indicate a major role of SUMOylation in the pathological aggregation of α-synuclein and Lewy body formation. Therefore, SUMOylation blockers provide a novel strategy to prevent intracellular α-synuclein accumulation, aggregation and spreading in PD. , and co-immunoprecipitation with PIAS1 or PIAS2 was detected with anti-myc (upper panel). Input levels were determined using anti-myc (lower panel). Graph depicts the percent of myc-PIAS1 and myc-PIAS2 co-immunoprecipitated with HA-α-synuclein relative to the total amount of each myc protein added per immunoprecipitation. B, PIAS2 was immunoprecipitated from rat brain using anti-PIAS2 antibody (lower panel), and co-immunoprecipitation was determinedwith anti-α-synuclein antibody (upper panel). C, In vitroSUMOylation of α-synuclein by PIAS2. His-α-synuclein was incubated with SUMOylation components and PIAS2. Levels of SUMOylated α-synuclein in relation to non-SUMOylated α-synuclein were quantified with anti-α-synuclein (graph). D, SUMOylated proteins from transfected HEK293 cells were immunoprecipitated with anti-Flag antibody and immunoprecipitates were further incubated with the purified deSUMOylase Ulp1 (lanes 3, 4 and 6). SUMOylated α-synuclein was detected with anti-α-synuclein (first panel). Immunoprecipitated SUMOylated proteins were detected with anti-Flag antibody (second panel). Graph represents the percent of SUMO-α-synuclein in cells (lanes 2 and 5) relative to non-SUMOylated α-synuclein. E, PIAS2 knockdown decreases α-synuclein SUMOylation. HEK293 cells were transfected in the presence of siRNA control or a PIAS2 siRNA. Graphs represent the percent of SUMO-α-synuclein in cells relative to nonSUMOylated α-synuclein and the percent of PIAS2 relative to β-actin. Values represent the average ± S.E.M. of 3 experiments. *, ** Different from control at p < 0.05 and 0.01, respectively (Student's t-test).
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cells (Fig. 1A) , in vitro pull-down assays ( Fig. S1A ) and rat brain tissues (Fig. S1B ). However, a direct comparison with PIAS2 in cells and in in vitro binding assays indicates that the interaction of A, Inhibition of SIAH-2-mediated monoubiquitination by PIAS2. In vitro SUMOylation/ubiquitination reactions were carried out by incubating His-α-synuclein with purified SUMOylation components for 60 min, followed by the addition of ubiquitination components for another 60 min. Levels of His-α-synuclein monoubiquitination were determined with anti-α-synuclein. Graph shows the percent of SIAH-2-dependentα-synuclein monoubiquitination, with and without GST-PIAS2 by comparing lanes 2 and 4. B, PIAS2 inhibits Nedd4-mediated α-synuclein ubiquitination. Conditions were the same as in A. Graph depicts the percent ofNedd4-dependentα-synuclein ubiquitination in the absence and in the presence of GST-PIAS2. C, PIAS2 decreases α-synuclein monoubiquitination in cells. Ubiquitinated proteins from transfected HEK293 cells were immunoprecipitated with anti-Flag antibody and monoubiquitinated α-synuclein was detected with anti-α-synuclein (first panel). Graph depicts the percent of monoubiquitinated α-synuclein in cells relative to unmodified α-synuclein. D, HEK293 cells were transfected as indicated, and in the presence of siRNA control or PIAS2 siRNA. Immunoprecipitation was carried out and analyzed as in C. Graph represents the percent of monoubiquitinated α-synuclein in cells relative to unmodified α-synuclein. Values represent the average ± S.E.M. of 3 experiments. *, **, *** Different from control at p < 0.05, 0.01 and 0.001, respectively (Student's t-test).
α-synuclein and PIAS1 is much weaker than PIAS2 (Figs. 1A and S1A). Thus, in subsequent experiments we studied in more detail the interaction of PIAS2 and α-synuclein .   137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173  174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204 Submission PDF Fig. 3 . SUMOylation by PIAS2 regulates α-synuclein levels and degradation. A, PIAS2 increases the steady-state levels of α-synuclein in transfected HEK293 cells. Graph depicts the percent of α-synuclein steady-state levels relative to β-actin at increasing amounts of myc-PIAS2. B, Endogenous levels of α-synuclein increase upon myc-PIAS2 transfection. C, PIAS2 knockdown decreases endogenous α-synuclein levels. HEK293 cells were transfected with siRNA control or siRNA to PIAS2. Endogenous levels of α-synuclein were determined using anti-α-synuclein antibody. D, PIAS2 prolongs α-synuclein half-life in transfected HEK293 cells treated with 50 μM cycloheximide. Graph depicts α-synuclein levels relative to β-actin in the presence of PIAS2 (•) or control LacZ (○). E, PIAS2 elevates α-synucleinin extracellular medium. Levels of α-synuclein in intracellular and extracellular HEK293 cell compartments were monitored with anti-HA (upper panels). Total protein loading was determined by Ponceau S staining (lower panels). Graph depicts the percent of α-synuclein in the medium relative to total protein loading monitored by Ponceau S staining. Values represent the average ± S.E.M. of 3-4 experiments. *, **, *** Different from control at p < 0.05, 0.01 and 0.001, respectively.
Repeated measures one-way ANOVA with Bonferroni post-hoc test (A) or Student's t-test (B-E).
PIAS2 increased α-synuclein SUMOylation in vitro (Fig. 1C) . Basal levels of SUMOylated α-synuclein were observed in the absence of PIAS2, which is consistent with the ability of the E2 conjugating enzyme UbcH9 to promote limited SUMO transfer to substrates in the absence of E3 SUMO-ligases (26) . Nevertheless, very small amounts of PIAS2, from 50ng per reaction, significantly increased SUMOylated α-synuclein levels by almost 3 fold (Fig. 1C, graph) . The size of the SUMOylated α-synuclein product by PIAS2 was consistent with modifications by two individual SUMO1 molecules at two different sites, since SUMO1 alone cannot form polySUMO chains (27, 28) . In agreement, methylated SUMO, which does not allow the formation of chains (29), did not affect the SUMOylation profile of α-synuclein ( 
S2A
). In addition, we observed the accumulation of high molecular weight α-synuclein species (above 250 kDa) in the presence of PIAS2 with either SUMO1 or methylated SUMO1 (Figs. 1C  and S2A ), suggesting the formation of α-synuclein aggregates, a phenomenon characterized in detail in Fig. 5 .
PIAS2 significantly increased α-synuclein SUMOylation in cultured cells (Figs. 1D) . Treatment of SUMO1-immunoprecipitates with the purified deSUMOylase Ulp1 (30) removed all SUMO conjugates and abolished the SUMOylated α-synuclein signal (Fig. 1D, lanes 3, 4 and 6) , confirming the specificity of SUMO1-α-synuclein conjugates. Longer exposure of the blots also demonstrates low levels of α-synuclein SUMOylation in the absence of PIAS2 (Fig. S2B ).
In agreement with its weaker binding to α-synuclein (Fig.  1A) , PIAS1 promoted much less α-synuclein SUMOylation in cells when compared to PIAS2 (Fig. S2C) . On the other hand, addition of the catalytic region of the E3 SUMO-ligase RanBP2 significantly increased the in vitro SUMOylation of α-synuclein ,   273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340 Submission PDF Fig. 5 . Elevated SUMOylated α-synuclein and SUMOylation components in PD brains. A, Homogenates prepared from substantia nigra of PD and control patients were probed with anti-PIAS2 antibody (upper panel). Graph depicts PIAS2 levels normalized to β-actin. B, Homogenates from frontal cortex tissue of PD with dementia and matched controls were analyzed and quantified as in A. C, Substantia nigra tissues of PD and controls patients were homogenized in formic acid and probed with anti-SUMO1 antibody (upper panel). Graph depicts SUMO1 levels normalized to β-actin. D, Homogenates from substantia nigra tissue ofPD and controls were incubated with proteinase K for 30 minutes and probed with anti-SUMO1 antibody (upper panel). A loading control was included by immediately adding 2% SDS to the samples (lower panel). Graph depicts SUMOylated protein levels of PD after 30 min proteinase K normalized to SUMOylated protein levels in untreated substantia nigra samples. E, Homogenates from frontal cortex tissues of PD with dementia and matched controls were immunoprecipitated with anti-SUMO1 antibody (middle panel). Levels of SUMOylated α-synuclein were determined using anti-α-synuclein antibody (upper panel). Lower panel shows the input levels of α-synuclein.Graph depicts SUMOylated α-synuclein levels normalized to non-SUMOylated α-synuclein. F, Immunohistochemistry of substantia nigra from PD patients using anti-SUMO1 antibody. Control lacks the primary antibody. Arrow points to a SUMO1-positive Lewy bodies. Arrowheads point to control unstained Lewy bodies. Sections were counterstained with hematoxylin. Scale bars, 10μm. *, ** Significantly different from control at p < 0.05 and 0.01, respectively (Student's t-test).
but without the formation of high molecular weight α-synuclein species (Fig. S2D) .
α-Synuclein has two lysine consensus sites for SUMOylation, K96, and K102 (22) . Nevertheless, mass spectrometry analysis revealed that 11 of 15 α-synuclein lysines are SUMOylated (25) . In support of widespread SUMOylation of α-synuclein lysines by PIAS2, we found that mutation of the α-synuclein lysines K96 and 102R decreased SUMOylation in cells by only 30% (Fig. 1D,  graph) . Most importantly, partial knockdown of PIAS2 by siRNA significantly decreased the levels of SUMOylated α-synuclein (Fig. 1E) . siPIAS2 also decreased the steady-state levels of α-synuclein (Fig. 1E, fourth panel, characterized in detail in Fig. 3) . However, siPIAS2 still decreased the levels of SUMO-α-synuclein by 50% after correcting for the lower steady-state levels of α-synuclein (Fig. 1E, graph) .
Inhibitory role of SUMOylation on α-synuclein ubiquitination
SUMOylation and ubiquitination target lysine residues, but the relationship between these modifications has not been investigated for α-synuclein. We observed that in vitro SUMOylation by PIAS2 decreased by 80% the monoubiquitination of α-synuclein promoted by SIAH-2 ( Fig. 2A, graph) . In addition, we noticed a decrease in PIAS2 levels in the presence of SIAH-2 ( Fig. 2A , compare lanes 3 and 4). This was due to the formation of high molecular weight GST-PIAS2 species that were retained in the stacking gel following the prolonged SUMOylation/monoubiquitination assays, so that less monomeric GST-PIAS2 remained in the presence of SIAH-2 (Fig. S3) . As control, the addition of PIAS2 without the SUMOylation components (SUMO E1 and UbcH9) had no effect on in vitro α-synuclein monoubiquitination (Fig. S4) , indicating that SUMOylation is responsible for the decrease in α-synuclein monoubiquitination.
SUMOylation by PIAS2 significantly decreased the in vitro ubiquitination of α-synuclein promoted by Nedd4 (Fig. 2B, compare lanes 3 and 4, graph) . Therefore, PIAS2-mediated SUMOylation negatively modulates different forms of α-synuclein ubiquitination.
Ectopic expression of PIAS2 lead to a 70% decrease in α-synuclein monoubiquitination levels in cells (Fig. 2C, graph) . Conversely, PIAS2 knockdown by siRNA increased the levels of monoubiquitinated α-synuclein by SIAH-2 by more than 2 fold (Fig. 2D) , supporting the role of PIAS2-mediated SUMOylation in counteracting α-synuclein monoubiquitination in cells.
Role of SUMOylation in α-synuclein degradation We found that PIAS2 increased the steady-state levels of α-synuclein by up to 3 fold (Fig. 3A) but it did not modify the steady-state levels of the control protein LacZ (Fig. S5) . Endogenous α-synuclein levels were increased 2 fold by PIAS2 overexpression (Fig. 3B) , whereas PIAS2 knockdown downregulated endogenous α-synuclein (Fig. 3C) . Moreover, PIAS2 prolonged the half-life of α-synuclein in the presence of the protein synthesis inhibitor cycloheximide (Fig. 3D) , suggesting that PIAS2-dependent SUMOylation leads to α-synuclein accumulation by reducing its degradation.
Since α-synuclein export has been proposed to spread PD, we monitored extracellular α-synuclein levels. We found that overexpression of PIAS2 increased the levels of extracellular α-synuclein as well (Fig. 3E) .
To explore the physiologic relevance of α-synuclein SUMOylation, we used ginkgolic acid, an E1 SUMO inhibitor (31) . Ginkgolic acid decreased the steady-state levels of α-synuclein in cells by up to 90% (Fig. S6A) , and this was preventable by the proteasome inhibitor lactacystin, suggesting that SUMOylation inhibition accelerates α-synuclein degradation by the proteasome. Ginkgolic acid also downregulated the endogenous levels of α-synuclein in primary neuronal cultures (Fig. S6B) , confirming the role of SUMOylation in regulating endogenous α-synuclein levels.
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We next investigated the presence of α-synuclein SUMOylation in normal human brain tissue. We immunoprecipitated SUMOylated proteins from human frontal cortex and identified a SUMOylated α-synuclein signal in the human brain (Fig. S6C) . Treatment of the immunoprecipitate with the de-SUMOylase Ulp1 abolished the SUMOylated-α-synuclein signal (Fig. S6C,  lane 2) , indicating that SUMOylation of α-synuclein occurs in vivo.
SUMOylation of mutant α-synuclein species and aggregation SUMOylation of the α-synuclein disease mutants A30P, A53T, and E46K was several-fold higher than the wild type α-synuclein in vitro (Fig. 4A, graph) . Addition of PIAS2 further increased SUMOylation of all α-synuclein types, though the percent of SUMOylation increase promoted by PIAS2 was similar among wild type and disease mutants (Fig. 4A) . Moreover, SUMOylation of the disease mutants by PIAS2 led to the formation of highmolecular weight α-synuclein species suggestive of aggregates, which were much more prominent in all disease mutants than wild type α-synuclein (Fig. 4A, middle panel) .
α-Synuclein disease mutants were 2-3 times more SUMOylated in cells in the presence of PIAS2 when compared to the wild type protein (Fig. 4B) . In agreement, the steady-state levels of α-synuclein disease mutants were more pronouncedly increased by PIAS2 compared with the wild type protein (Fig. S7A) . Furthermore, α-synuclein becomes partially resistant to proteinase K treatment in the presence of PIAS2 (Fig. S7B) , suggesting that SUMOylation increases the aggregation state of α-synuclein in cells. Resistance to proteinase K treatment was more pronounced with α-synuclein disease mutants (Fig. S7B) , which is compatible with their higher aggregation state following PIAS2-mediated SUMOylation.
We then investigated the aggregation and inclusion formation of α-synuclein by immunocytochemistry. In order to improve the sensitivity of our assay, we treated cells with proteinase K prior to fixation for immunocytochemistry (32) . Levels of proteinase Kresistant α-synuclein aggregates were higher in disease mutants than wild type in the presence of PIAS2 (Figs. 4C and 4D) . No significant inclusion formation was observed when a control protein (myc-FKBP12) was transfected instead of myc-PIAS2 (Figs. 4C and 4D) . Moreover, SUMO1 was present in α-synuclein inclusions (Fig. S8) .
Levels of SUMO-α-synuclein and SUMOylation machinery in PD patients
Since α-synuclein SUMOylation takes place in normal human brain tissues (Fig. S6C) , we investigated the levels of PIAS2 in PD brains. We observed that the levels of PIAS2 are about 3 fold higher in the substantia nigra of PD patients (Fig. 5A ) and in the cerebral cortex of PD subjects that progressed to dementia (Fig. 5B) . Upon solubilization of brain tissues with formic acid (33), the total levels of SUMOylated proteins are 2 fold higher in the substantia nigra of PD brains compared to that of controls (Fig. 5C ). In addition, we treated with proteinase K to determine the levels of aggregated proteins (32, 34) . The substantia nigra of PD subjects contained significantly more proteinase Kresistant SUMOylated proteins than controls (Figs. 5D) . Most importantly, the levels of SUMOylated α-synuclein isolated by immunoprecipitation are strikingly increased in the cerebral cortex of PD patients with dementia (Fig. 5E ). In addition, we found strong immunoreactivity of SUMO1 in approximately 25% (10 out of 41 α-synuclein-positive) Lewy bodies of 3 different PD cases (Fig. 5F ) while PIAS2 was detected in approximately 50% (18 out of 37 α-synuclein-positive) Lewy bodies in 3 different PD cases (Fig. S9 ).
Discussion
Our observations indicate that increased SUMOylation may play a role in promoting α-synuclein accumulation and aggregation in PD. We demonstrated that α-synuclein is SUMOylated by PIAS2 and this is associated with α-synuclein accumulation, aggregation and increased α-synuclein levels in the extracellular medium. SUMOylation by PIAS2 promotes the formation of α-synuclein inclusions in cells even in the absence of proteasome inhibitors. Furthermore, SUMOylation decreases the ubiquitination of α-synuclein by both SIAH and Nedd4, indicating a general inhibitory role of SUMOylation on α-synuclein ubiquitination. Most importantly, SUMOylated α-synuclein and PIAS2 are markedly elevated in the substantia nigra of PD brains, and Lewy bodies are positive for both SUMO1 and PIAS2.
We found that SUMOylation increases α-synuclein aggregation by two self-reinforcing mechanisms. First, SUMOylation by PIAS2 directly promotes the aggregation of α-synuclein. Second, SUMOylation impairs α-synuclein ubiquitination, which prevents α-synuclein degradation. This causes the accumulation of α-synuclein and facilitates its aggregation. In addition to blocking α-synuclein degradation, SUMOylation by PIAS2 increased the release of α-synuclein to the extracellular medium. The increase in extracellular α-synuclein may be due to the α-synuclein accumulation secondary to SUMOylation or indirectly by SUMOylation of the endosomal sorting complex, which is known to increase α-synuclein extracellular export (35) .
α-Synuclein contains two lysine residues, K96 and K102, which follow the consensus for SUMOylation (22) . A study using α-synuclein mutated at K96 and K102 suggested that SUMOylation of these residues decreases the aggregation of α-synuclein (25) . A caveat of using K96/102 mutants is that at least 9 additional α-synuclein lysines are SUMOylated in cells (25) . In agreement, we found that mutations on K96 and K102 caused only a 30% decrease in the SUMOylation of α-synuclein by PIAS2. In support of our findings, SUMOylation of numerous proteins by SUMO ligases occur in lysines that lack consensus sequence for SUMO conjugation (36) . Thus, the effects of K96/102 mutants on aggregation observed in a previous study (25) may be related to a change in the specific amino acids rather than SUMOylation changes.
SUMOylation may have opposite effects on ubiquitination of target proteins. It can either prime SUMO-targeted ubiquitin ligases and increase ubiquitination or compete for the target lysines preventing the ubiquitin linkage (37) . The latter appears to be the case for α-synuclein and PIAS2. In agreement, the E1 SUMO inhibitor ginkgolic acid accelerated the proteasomal degradation of α-synuclein by relieving the inhibition exerted on its ubiquitination. This effect was more pronounced in transfected cells than in neurons, suggesting that endogenous neuronal α-synuclein may have slower half-life or additional regulatory mechanisms that affect its proteasomal degradation, like glycation (38) .
Previous studies reported that proteasomal inhibition promotes α-synuclein inclusions that are SUMOylated but did not ascribe a direct effect of SUMOylation on aggregation (23, 24) . Proteasomal inhibition also favors the formation of monoubiquitinated α-synuclein aggregates (17, 18) . We now show that PIAS2-mediated SUMOylation per se increases the aggregation of α-synuclein under intact proteasomal activity. It is possible that akin to monoubiquitination (17) , SUMOylation increases the hydrophobicity of α-synuclein and directly facilitates its aggregation.
α-Synuclein may be SUMOylated by additional SUMOligases, albeit with different efficiencies. We found that PIAS1 also interacts with α-synuclein in the brain, but direct comparison by employing the same antibody for co-immunoprecipitations or recombinant α-synuclein in pull down assays indicates weaker interaction of human PIAS1 with α-synuclein when compared to human PIAS2. In agreement with a previous study (25) , we found that the catalytic portion of RanBP2 SUMOylates α-synuclein in vitro. However, we did not detect formation of highmolecular weight or aggregated α-synuclein species following 545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594 Submission PDF RanBP2 SUMOylation. In this context, it is possible that the strong binding of PIAS2 to α-synuclein also contributes to the efficient aggregation of SUMOylated α-synuclein, an effect not shared by the catalytic part of RanBP2.
We found that the α-synuclein disease mutants are more prone to SUMOylation and SUMOylation-mediated aggregation than the wild type protein. Further studies are necessary to better understand the mechanisms underlying the increased SUMOylation among α-synuclein disease mutants.
Abnormal SUMOylation has been implicated in the pathology of neurodegenerative diseases, including Huntington's, Alzheimer's and Amyotrophic Lateral Sclerosis (39) (40) (41) (42) (43) . SUMO1 was also suggested to be present in some Lewy body preparations of PD and DLB brains (24) . Unilateral rotenone-lesioned mouse models of PD have increased levels of SUMO1 (44) . Our observation of a striking increase in SUMOylated proteins and SUMOylated α-synuclein in PD tissues provides compelling evidence supporting a general upregulation of SUMOylation in PD and of the SUMOylated α-synuclein in particular. Our results demonstrating an increase in PIAS2 expression in PD tissues and the presence of SUMO1 and PIAS2 in Lewy bodies provides a causal mechanism underlying the accumulation of SUMOylated α-synuclein. Therefore, SUMOylation blockers may provide a novel strategy to prevent intracellular α-synuclein aggregation and the spread of α-synuclein.
Materials and Methods
In vitro SUMOylation assays
Recombinant His-α-synuclein was incubated in medium containing 40 mM Tris-HCl (pH 7.6), 5 mM MgCl 2 , 2 mM DTT, 1 mM ATP-γ-S, 5 μg SUMO1, 1 μM SUMO1 aldehyde, 100 ng SUMO E1 (SAE1/UBA2; activating enzyme) and 200 ng UbcH9 (SUMO E2; conjugating enzyme), in the presence or absence of 200 ng PIAS2 or RanBP2△FG (E3 SUMO-ligases), unless specified otherwise. Reactions were incubated at 37 0 C for 1 hour and resolved on PAGE-SDS gels. SUMOylated α-synuclein was determined by Western blot using anti-α-synuclein antibody.
Further experimental details are provided in Supporting Information text.
